Biolase, Inc. · OTC:BIOLQ
Biolase — Biolase Technology — Rodman & Renshaw Annual Global Investment Conference 2011
37 slides from Biolase's conference presentation, Sep 12, 2011
Slide 1: BIOLASE Technology, Inc.
BIOLASE Technology, Inc. Federico Pignatelli, Chairman, CEO & President Fred Furry, CFO & VP Finance Rodman & Renshaw Annual Global Investment Conference September 11-13, 2011, New York City
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management's beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "e
Slide 3: BIOLASE is About Revolutionizing Surgery in Dentistry and Medicine
BIOLASE is About Revolutionizing Surgery in Dentistry and Medicine BIOLASE is NOT just another medical device company! PAGE 3
Slide 4: How has BIOLASE Revolutionized Surgery?
How has BIOLASE Revolutionized Surgery? Conventional Surgical Devices include the scalpel, high speed drill, electrosurge, electric bone saws, and heat generating lasers. Years of engineering and research at BIOLASE led to the discovery that the Er,Cr:YSGG (2796nm) laser crystal (Erbium, Chromium do
Slide 5: Why BIOLASE WaterLase Technology in Dentistry?
Why BIOLASE WaterLase Technology in Dentistry? Traditional high-speed drills work by FRICTION which creates HEAT which causes PAIN. This PAIN necessitates injections of ANESTHESIA which results in PAIN and NUMB LIPS. In addition, the lack of feeling from the numbing injections can lead to THERMAL DA
Slide 6: Traditional Dentistry
Traditional Dentistry Traditional Dentistry The painting Cavadenti, the Tooth Puller, by Caravaggio, circa 1608 PAGE 6
Slide 7: Alternative Hi-Tech Dentistry
Alternative Hi-Tech Dentistry Atraumatic Pediatric Tooth Extraction The aiming beam on the NEW WaterLase iPlus is green. This red beam featured in the previous generation of WaterLase products does not cut the tissue. Tissue is cut biologically, with water at the molecular level. Using BIOLASE Water
Slide 8: Alternative Dentistry is Less Frightening
Alternative Dentistry is Less Frightening Traditional Surgical Approach: Using the dental drill offers more of the same which is pain, local anesthetic, swelling, pain killers, micro-fractures and cross contamination. Alternative, Hi-tech, Biological Surgical Approach: Using WaterLase technology off
Slide 9: The Untapped Portion of the Dental Market
The Untapped Portion of the Dental Market How BIOLASE WaterLase technology can increase a dentist's patients by 33%. According to the ADA...nearly 25% of all Americans avoid dentists because they are afraid of dental drills and needles. There are 160,000 dentists currently serving a population of 30
Slide 10: Waterlase Technology R.O.I.
Waterlase Technology(tm) R.O.I. Waterlase MD Turbo enables dentists to perform procedures they currently refer out to specialists, for example: Gingivectomy for Immediate Subgingival Class V Restoration = $160 Perio Treatment Quadrant of 4-7mm pockets 4 @$375/ea = $1,500 Hard-tissue Crown Lengthenin
Slide 11: Technology Supported by Scientific Data
Technology Supported by Scientific Data Substantial Data: The effectiveness of dental lasers is proven and well researched. Clinical data and peer- reviewed specialty journals substantiate the effectiveness of laser treatment in a wide variety of procedures. PAGE 11
Slide 12: Dental Schools Teaching WaterLase Technology around the World
Some of the Dental Schools that are Teaching WaterLase Technology around the World PAGE 12
Slide 13: WaterLase High Speed Cutting
WaterLase High Speed Cutting PAGE 13
Slide 14: WaterLase vs. Drill
WaterLase vs. Drill PAGE 14
Slide 15: Patients Urged to Ask Dentists About Risk of Cross Contamination
1. Dental Health Magazine 2. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie Morrison, DDS, MS, FRCD(C); Susan Conrod, DDS JCDA • www.cda-adc.ca/jcda • February 2009, Vol. 75, No. 1. 3. Contaminated dental instruments: Smith A, Dickson M, Aitken J, Bagg J.J
Slide 16: No Pain, No Tissue Damage & No Risk of Cross-Contamination
Because NO Pain, NO Tissue Damage & NO Risk of Cross-Contamination: WaterLase MD(tm) reduced E. faecalis 2.86 times more effectively than NaOCl3 1. Dental Burs and Endodontic Files: Are Routine Sterilization Procedures Effective?: Archie Morrison, DDS, MS, FRCD(C); Susan Conrod, DDS JCDA • www.cda-a
Slide 17: Intellectual Property
Award winning IP: Recognized for innovation, leadership, and the development of numerous disruptive technologies, most notably the development of a new surgical system to cut human tissue in a biological and atraumatic way. Received Astrum Award at MDB Capital's 2011 Bright Lights Conference. Strate
Slide 18: Patent Portfolio Current Status
Current Status: BIOLASE currently has 274 issued and pending patents, 70% of which are related to our core Er;Cr:YSGG technology and medical lasers. Filing costs and maintenance are closely monitored. Funding for redundant patents and patents with a low- probability for issuance are stopped. Patent
Slide 19: The Value of Technology
The Value of Technology Dental Lasers: Allow dentists to perform their current daily procedures more efficiently plus perform a wide variety of dental procedures they otherwise may currently be referring out of their practices. Cone Beam 3-D Dental Imaging: Provides a high-definition, digital image
Slide 20: Current Line of BIOLASE Products
Current Line of BIOLASE Products All-tissue dental lasers: Our all-tissue lasers include our new flagship laser, the revolutionary WaterLase iPlus, and the WaterLase MD Turbo. Diode soft-tissue dental lasers: Our soft tissue lasers include the ezLase total diode solution, which offers power and port
Slide 21: Expanding in Dentistry
Laser Toothbrush BIOLASE is currently developing a laser toothbrush in connection with a license agreement with The Proctor and Gamble Company ("P&G"). Research indicates that a laser toothbrush will whiten teeth, disinfect teeth and gums, bio-stimulate teeth and gums, relieve pain, and perform phot
Slide 22: Expanding Beyond Dentistry: Ophthalmology, Orthopedics, Dermatology
Ophthalmology: We currently hold 13 issued and 20 pending U.S. and International patents in four patent families in the field ophthalmology, giving us a wide range of applications and coverage. Our technology has the capability to restore the elasticity of the optic nerve and muscle allowing the eye
Slide 23: Foundation for a Successful Recovery
Why a turnaround of BIOLASE today will be quicker and more effective than in the past: BIOLASE has a better organizational structure, better cost control, and more efficient & effective management than ever before. The BIOLASE brand is currently known by over 80% of North American dentists and is gr
Slide 24: How BIOLASE is Positioned in the Dental Market
How BIOLASE is Positioned in the Dental Market BIOLASE United States BIOLASE International Total: 12,500 Total: 5,500 Grand Total: 18,000 2,800 2,700 5,700 6,800 PAGE 24
Slide 25: Owning the Hard Tissue Dental Laser Market
Owning BIOLASE Means Owning the Hard Tissue Dental Laser Market... Biolase 80% Source: Biolase Technology Licensing Reports PAGE 25
Slide 26: and the Overall Dental Laser Market
....and the Overall Dental Laser Market. Biolase 45% Source: iData Research Inc. 2009 US Dental Laser Market: Hard & Soft Tissue PAGE 26
Slide 27: Our Market Opportunity in Dentistry
Our Market Opportunity in Dentistry BIOLASE's current market penetration is less than 1.5% of the potential global market. 176,000 dentists in the US and Canada.1 Over 1.2 million dentists in 134 countries.2 18,000 systems in over 11,000 practices. Every 1% of further market penetration is equal to
Slide 28: Global Opportunity in Emerging Dental Markets
Global Opportunity in Emerging Dental Markets North America 176,000 dentists 1 dentist / 1,900 population Western Europe 240,000 dentists 1 dentist / 1,800 population Latin America 298,000 dentists 1 dentist / 5,600 population Eastern Europe 120,000 dentists 1 dentist / 4,000 population Middle East
Slide 29: BIOLASE is the Global Leader in Dental Lasers
BIOLASE is the Global Leader in Dental Lasers: Over 18,000 laser systems sold to over 11,000 dental practices in over 50 countries worldwide. We have over 160 employees worldwide We have sales offices in the U.S., Floss (Germany), Madrid (Spain), Shanghai (China), and Mumbai (India), with expansion
Slide 30: Operations: Manufacturing and Research & Development
Operations Manufacturing and Research & Development Our 57,000 sq. ft. facility houses administrative, sales, marketing, customer care, training, R&D and manufacturing. It is ISO 9001 certified and FDA GMP with clean room operations. Nearly 100% of our components and subassemblies are manufactured i
Slide 31: Recent Developments
Recent Developments Russell Global Index: BIOLASE joined the Russell Global Index and Russell 2000(r) Index in June 2011. Ophthalmology: In June 2011, BIOLASE entered into an agreement with Daniel S. Durrie, M.D., an internationally recognized refractive surgeon, to serve as BIOLASE's primary ophtha
Slide 32: Recent Developments
Recent Developments Legal Settlement: In June 2011, BIOLASE reached a final settlement with Philips Electronics (NYSE:PHG) and Discus Dental LLC, regarding the litigation that Discus brought against BIOLASE in 2010 (Discus was subsequently acquired by Philips). In the litigation, Discus asserted var
Slide 33: Recent Developments
Recent Developments Digital Imaging Sales: At the end of the second quarter, BIOLASE received its first orders for its state of the art dental imaging devices for delivery in the third quarter. Additions to the Management Team: BIOLASE has recently hired Richard Whipp as Director of Operations and E
Slide 34: Management and Employee Stakeholders
Management and Employee Stakeholders Management and Employees: BIOLASE's entire executive team holds options to purchase common stock. Further, in December 2010, the Board of Directors granted approximately 1.5 million stock options to ALL of the employees of the Company. These options have a strike
Slide 35: Chart & Financial History
Volume: Millions of Shares 0.5 1.0 Chart & Financial History 20 15 10 5 BLTI SHARE PRICE Guidance 1994-2006 Pignatelli Chairman of the Board Exclusive distribution partnership with Henry Schein Aug 2006-Aug 2010 Aug 2010-Present Pignatelli CEO & Board Chairman 1998 FDA Clearance WaterLase PAGE 35
Slide 36: Relative Valuations
Symbol Name Recent Price 9/1/11 Current Market Value/ 2011 Revenue Market Cap Price/ Earnings Dividend Yield 4 Year EPS Growth Avg 4 Year Revenue Growth Est Revenue Growth 2011 BLTI BIOLASE Technology $3.00 2.6 $89M -- 4.00% Stock -60.0% -58.0% +150.0% Other Oral Care Other Oral Care Other Oral Care
Slide 37: BIOLASE Technology, Inc.
BIOLASE Technology, Inc. Federico Pignatelli, Chairman, CEO & President Fred Furry, CFO & VP Finance Rodman & Renshaw Annual Global Investment Conference September 11-13, 2011, New York City PAGE 37
Biolase Technology — Rodman & Renshaw Annual Global Investment Conference 2011 on 6ix